文献速递造血干细胞移植与细胞治疗

T细胞充足HLA相合移植物与T细胞去除HLA不合移植物在先天性免疫缺陷病中的比较

T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity.
PubMed 文献 · Blood Adv · 2022-01-01

本研究首次比较了先天性免疫缺陷病(IEI)患儿接受T细胞充足HLA相合移植物(使用阿仑单抗,n=117)与T细胞去除HLA不合移植物(使用TCRαβ/CD19去除,n=47)的移植结局,患者于2014至2019年间首次接受造血细胞移植(HCT)。全队列3年总生存(OS)为85%(77%-90%),无事件生存为79%(69%-86%)。在5岁以下患儿中,两种移植物3年OS相当(T细胞充足组88% vs T细胞去除组87%);在5岁以上患儿中,T细胞去除组OS显著低于T细胞充足组(55% vs 87%,P=0.03)。

要点

  • 全队列3年OS为85%(77%-90%),无事件生存为79%(69%-86%)。
  • 5岁以下患儿中,T细胞充足与T细胞去除移植物3年OS相当(88% vs 87%)。
  • 5岁以上患儿中,T细胞去除组OS显著低于T细胞充足组(55% vs 87%,P=0.03)。

核心结论

  • 数据表明,对于需要异基因移植的年幼IEI患儿,使用TCRαβ/CD19去除的不合供者移植是一种极好的替代选择。

研究设计与样本

  • 本报告首次比较了2014至2019年间首次接受HCT的IEI患儿中,使用阿仑单抗的T细胞充足HLA相合移植物(n=117)与使用TCRαβ/CD19去除的T细胞去除HLA不合移植物(n=47)的移植结局。
  • 所有患者均接受基于曲奥舒凡的预处理,DNA修复疾病患者除外。
  • T细胞充足移植物中,干细胞来源为骨髓25例(21%)、外周血干细胞(PBSC)85例(73%)、脐带血7例(6%)。
  • TCRαβ/CD19去除在来自45例单倍体相合父母供者和2例不合无关供者的PBSC上进行。

主要发现

  • 全队列3年总生存(OS)为85%(77%-90%),无事件生存为79%(69%-86%)。
  • 5岁以下患儿中,T细胞充足移植物3年OS为88%(76%-94%),T细胞去除移植物为87%(64%-96%),两者相当。
  • 5岁以上患儿中,T细胞去除移植物OS为55%(23%-78%),显著低于T细胞充足移植物的87%(68%-95%)(P=0.03)。
  • III至IV级急性移植物抗宿主病发生率:T细胞充足骨髓8%、T细胞充足PBSC 7%、T细胞充足脐带血14%、T细胞去除PBSC 2%(P=0.73)。
  • T细胞去除移植物HCT后病毒血症发生率更高(P<0.001),CD3重建延迟(P=0.003)。

临床怎么用

  • 作者认为,对于需要异基因移植的年幼IEI患儿,使用TCRαβ/CD19去除的不合供者移植是一种极好的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic cell transplantation (HCT) has become standard-of-care for an increasing number of inborn errors of immunity (IEI). This report is the first to compare transplant outcomes according to T-cell-replete (ie, T-replete) HLA-matched grafts using alemtuzumab (n = 117) and T-cell-depleted (ie, T-depleted) HLA-mismatched grafts using T-cell receptor-αβ (TCRαβ)/CD19 depletion (n = 47) in children with IEI who underwent first HCT between 2014 and 2019. All patients received treosulfan-based conditioning except patients with DNA repair disorders. For T-replete grafts, the stem cell source was marrow in 25 (21%) patients, peripheral blood stem cell (PBSC) in 85 (73%), and cord blood in 7 (6%). TCRαβ/CD19 depletion was performed on PBSCs from 45 haploidentical parental donors and 2 mismatched unrelated donors. The 3-year overall survival (OS) and event-free survival for the entire cohort were 85% (77%-90%) and 79% (69%-86%), respectively. Analysis according to age at transplant revealed a comparable 3-year OS between T-replete grafts (88%; 76%-94%) and T-depleted grafts (87%; 64%-96%) in younger patients (aged <5 years at HCT). For older patients (aged >5 years), the OS was significantly lower in T-depleted grafts (55%; 23%-78%) compared with T-replete grafts (87%; 68%-95%) (P = .03). Grade III to IV acute graft-versus-host disease was observed in 8% of T-replete marrow, 7% of T-replete PBSC, 14% of T-replete cord blood, and 2% of T-depleted PBSC (P = .73). Higher incidence of viremia (P < .001) and delayed CD3 reconstitution (P = .003) were observed after T-depleted graft HCT. These data indicate that mismatched donor transplant after TCRαβ/CD19 depletion represents an excellent alternative for younger children with IEI in need of an allograft.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lum SH, Greener S, Perez-Heras I, et al. T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity. Blood Adv. 2022. PMID: 34972212. doi:10.1182/bloodadvances.2020004072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。